Search clinical trials for: Lumigan 0.03% Unit Dose

Total 107 results

Laboratoires Thea

Completed

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Primary Open Angle Glaucoma | Ocular Hypertension

France
Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Universitaire Ziekenhuizen KU Leuven
Allergan

Unknown

Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml (SPORTII)

Ocular Hypertension | Glaucoma

Belgium, Austria, Italy, Switzerland, United Kingdom
Allergan

Completed

A Study of Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUS)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

A Study of 0.03% Bimatoprost in the Treatment of Primary Open Angle Glaucoma and Ocular Hypertension (LOTUSDI)

Ocular Hypertension | Glaucoma, Open-Angle

China
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)

Ocular Hypertension | Glaucoma, Open-Angle

Korea, Republic of
Allergan

Completed

A Study of Bimatoprost 0.01% in the Clinical Setting (APPEAL-Taiwan)

Ocular Hypertension | Glaucoma, Primary Open Angle

Taiwan
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Rabin Medical Center

Completed

Treatment of Soft Tissue Expansion in Inactive Thyroid Eye Disease Patients Using Drops of Prostaglandin Analogues

Thyroid Associated Ophthalmopathies

Israel
University of California, San Diego

Completed

24-hour IOP-lowering Effect of 0.01% Bimatoprost

Ocular Hypertension | Glaucoma | Intraocular Pressure

United States
Northwestern University
Allergan

Completed

Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure

Intraocular Pressure | Nail Growth Cessation

United States
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

A Study of LUMIGAN® RC in the Clinical Setting

Ocular Hypertension | Glaucoma, Primary Open Angle

Canada
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Eyelashes

United States, Canada
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Chronic Spontaneous Urticaria

China
Theravance Biopharma

Completed

TD-0903 Pharmacokinetics Study in Healthy Participants With Supplemental Oxygenation

Acute Lung Injury (ALI) Due to Coronavirus Disease-2019 (COVID-19)

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Longbio Pharma

Recruiting

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

Seasonal Allergic Rhinitis

China
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
University of North Carolina, Chapel Hill
Naturex SA

Completed

Botanical Supplement Muscle Function and Lean Body Mass

Healthy Volunteers

United States
Seoul National University Hospital

Completed

Optimal Dose of i.v Oxycodone for Postoperative Pain

Pain

Korea, Republic of
Seoul National University Hospital

Withdrawn

Optimal Dose of i.v Oxycodone for Postoperative Pain After Laparoscopic Colorectal Surgery

Pain

Korea, Republic of
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
Allergan

Completed

Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Canada
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Pfizer

Completed

Acute Treatment Trial in Adult Subjects With Migraines

Migraine

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost, Latanoprost, and Travoprost in Patients With Elevated Intraocular Pressure (IOP) and Open-angle Glaucoma (OAG)

Ocular Hypertension | Open-Angle Glaucoma

United States
VA Eastern Colorado Health Care System
United States Department of Defense

Completed

Blister Packaging Medication to Increase Treatment Adherence and Clinical Response (BP)

Suicide, Attempted | Medication Adherence | Accidental Overdose | Deliberate Overdose

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
National Taiwan University Hospital

Completed

Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection

Hepatitis

Taiwan
Vistakon Pharmaceuticals

Completed

Safety and Efficacy of a Drug Delivery System in Glaucoma

Ocular Hypertension | Open-angle Glaucoma

United States
Allergan

Completed

Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues

Ocular Hypertension | Open Angle Glaucoma

United States
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
GangaGen, Inc.

Completed

Safety & Efficacy of an Antibacterial Protein Molecule Applied Topically to the Nostrils of Volunteers and Patients

Bacterial Infections | Infectious Disease

Singapore
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Santen SAS

Recruiting

3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or Keratoconjunctivitis (ALHENA)

Dry Eye Syndromes

France
Provectus Pharmaceuticals

Completed

Randomized Study of PH-10 for Psoriasis

Psoriasis

United States
Autoimmune Technologies, LLC

Completed

Safety Study of Flufirvitide-3 Nasal Spray in Healthy Subjects

Influenza

United States
Shire

Completed

Safety and Efficacy of ALX-0600 in Subjects With Active Crohn's Disease

Crohn's Disease

United States, Canada

3

Subscribe